A Revolutionary Rapid Alcohol Detoxification Drink
Quantum BioPharma is bringing innovative neuro disorders therapies to millions of patients in need.
MISSION STATEMENT
To develop novel solutions for brain and inflammatory disorders
VISION
To be a world class innovation driven biopharmaceutical company to improve the quality of life of patients
VALUES
Commitment, hard work and integrity
UNBUZZD™
Launching 2024
Created by Scientists & Expert Clinical Research Team at Quantum BioPharma
Led by Former Executives from Coca-Cola and Celsius Holdings
UNBUZZD™ is led by a very experienced and successful beverage team
Kevin Harrington
Kevin Harrington is the inventor of the infomercial, Shark on Shark Tank, Fortune 100 investor, philanthropist, and author. Kevin has launched over 1,000 products in over 100 countries in dozens of languages, creating over $6 billion in global sales, and was instrumental in the creation of Celsius’ influencer marketing program.
Gerry David
Gerry David is best known for his five-year tenure as Chief Executive Officer at zero-calorie fitness drink maker Celsius Holdings, Inc. (NASDAQ: CELH) where he spearheaded a turnaround that resulted in a global sales explosion, influx of capital from notable strategic investors, and a rise in market capitalization that increased shareholder value 35-fold by exceeding $9 billion.
John Duffy Jr.
John Duffy spent over 22 years in the Coca-Cola (NYSE: KO) system including roles of increasing responsibilities across multiple functions. In his last role at Coca-Cola as Vice President of National Sales, John led the customer management team responsible for the Coca-Cola systems’ largest foodservice distributor, Sysco.
Mental Alertness & Detoxification when Alcohol is Consumed
Through Science, Find Clarity™
UNBUZZD™
Year 2023 marks the first true convergence of science and accelerating alcohol metabolism. Until now, when one consumes excess alcohol, “time” has been the only answer to return to sobriety, creating a great need for a solution that provides faster and more effective recovery. In 2023, we are bringing out the science to find clarity. This is not just another hangover remedy!
We’re talking about UNBUZZD™, a new, great tasting functional beverage being developed by Quantum BioPharma with the expectations of providing relief from inebriation and accelerating alcohol metabolism leading to reduced Breath Alcohol Concentration (BrAC). No more hyperbole. Just Science.
LUCID-MS
Patented new chemical entity (NCE)
Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions. Lucid-MS has shown excellent results in several animal models, as demonstrated in the video below.
A sampling of the novel qualities of Lucid-MS include:
Excellent efficacy in various preclinical animal models
Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
Does not suppress immune system (non-immunomodulatory)
Potential oral administration with easy dosing regimen
Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.
Today there is no cure for Multiple Sclerosis.
Quantum BioPharma (“QNTM”) is trying to change this for millions of people.
Competitive Advantage / Value Proposition
-
World-Class Pipeline
Neurodegenerative and neuropsychiatric disease, multi-billion dollar markets, unmet need, decades of research de-risk our drugs
Lucid-MS: New Chemical Entity for Multiple Sclerosis, pre-clinical research re-established use of paralyzed rear legs in MS mouse model, research published in peer-reviewed journals. On 17th of January 2023 Quantum BioPharma has submitted its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first in-human safety and tolerability investigation
IP Estate: Quantum BioPharma has rights to patent families licensed on an exclusive basis
-
Elite Team
Quantum BioPharma’s flagship subsidiary led by Dr. Lakshmi Kotra, the recipient of the Julia Levy Award and a senior scientist at the Krembil Brain Institute, as well as the world-renowned University Health Network (UHN).
Quantum BioPharma has a world class team working full-time on pipeline development, with backgrounds at the FDA, major pharmaceuticals firms, and esteemed universities.
Quantum BioPharma team includes Julia Levy Award recipient, a distinguished award that has only been awarded to 8 recipients since its inception in 2005 (no other company can make this claim)
-
Market Cap Table
6 Class A shares
1,300,727 Class B shares
48,951 Options
138,077 Warrants
*Data current as of August 14, 2024
A balance sheet represented by no debt and enough working capital to carry operations of 2025
Developing novel myelin repairing compounds for the treatment of neurodegenerative and neuropsychiatric diseases
Two lead candidates to improve patient outcomes and address large populations ($23B multiple sclerosis market and $238B mental health market)
Phase-1 dosing of all patients completed for Lucid-MS (Lucid-21-302) for first in-human safety and tolerability investigation. This trial will be First In Class for its Multiple Sclerosis drug candidate
World class and experienced team of scientists, researchers and doctors from world class institutions or organizations
Latest News
© Copyright 2024 Quantum BioPharma. All Right Reserved. Powered by Issuer Direct.